▶ 調査レポート

乾癬治療の世界市場:市場規模、シェア、成長、動向、予測

• 英文タイトル:Psoriasis Treatment Market (Drug Class: TNF Inhibitors, Interleukin Inhibitors, Vitamin D Analogs, Corticosteroids, and Others; Route of Administration: Oral, Parenteral, and Topical; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Transparency Market Researchが調査・発行した産業分析レポートです。乾癬治療の世界市場:市場規模、シェア、成長、動向、予測 / Psoriasis Treatment Market (Drug Class: TNF Inhibitors, Interleukin Inhibitors, Vitamin D Analogs, Corticosteroids, and Others; Route of Administration: Oral, Parenteral, and Topical; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027 / TPM-NV163資料のイメージです。• レポートコード:TPM-NV163
• 出版社/出版日:Transparency Market Research / 2019年10月28日
• レポート形態:英文、PDF、200ページ
• 納品方法:Eメール
• 産業分類:製薬
• 販売価格(消費税別)
  Single User¥643,245 (USD5,795)▷ お問い合わせ
  Multi User¥976,245 (USD8,795)▷ お問い合わせ
  Global Site License¥1,309,245 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、乾癬治療の世界市場について調べ、乾癬治療の世界市場規模、市場動向、市場シェア、市場環境、市場予測、薬物クラス別(TNF阻害剤、インターロイキン阻害剤、ビタミンD類縁体、コルチコステロイドなど)分析、投与経路別(経口、非経口、および局所)分析、流通チャンネル別(病院薬局、小売薬局、およびその他)分析、関連企業情報などをまとめました。
・乾癬治療の市場概要
・乾癬治療の市場動向
・乾癬治療の世界市場規模・予測
・乾癬治療市場:薬物クラス別(TNF阻害剤、インターロイキン阻害剤、ビタミンD類縁体、コルチコステロイドなど)
・乾癬治療市場:投与経路別(経口、非経口、および局所)
・乾癬治療市場:投与経路別(経口、非経口、および局所)
・地域別分析(北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米)
・競争環境・関連企業分析

Even as healthcare, as a whole, is transitioning slowly towards value-based care for better patient outcomes and improved quality of life, increase in the prevalence of psoriasis, globally, is spurring investments toward its treatment and management methods. This has resulted in manufacturers in the psoriasis treatment market focussing on research & development for better disease management, which has led to the innovation of newer drugs that are more efficient. For instance, in April 2019, Samsung Bioepis’ – Eticovo, the second biosimilar of Etanercept, was approved by the FDA for the treatment of psoriasis in moderate to severe cases.

With biologics gradually losing their exclusivity and becoming increasingly accessible, they are expected to positively contribute to the growth of the global psoriasis treatment market. According to this study by Transparency Market Research, in 2018, the market was valued at ~US$ 13.8 Bn, and is set to hit the ~US$ 35.7 Mn by the end of the forecast period.

レポート目次

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Psoriasis Treatment Market

4. Market Overview

4.1. Introduction

4.1.1. Market Definition

4.1.2. Industry Evolution / Developments

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Psoriasis Treatment Market Analysis and Forecast, 2017–2027

4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

5.1. Regulatory Scenario by Region/Key Country

5.2. Psoriasis Treatment Market Pipeline Analysis

5.3. Key Mergers & Acquisitions

6. Global Psoriasis Treatment Market Analysis and Forecast, by Drug Class

6.1. Introduction & Definition

6.2. Key Findings / Developments

6.3. Psoriasis Treatment Market Value Forecast, by Drug Class, 2017–2027

6.3.1. TNF Inhibitors

6.3.2. Interleukin Inhibitors

6.3.3. Vitamin D Analogs

6.3.4. Corticosteroids

6.3.5. Others

6.4. Market Attractiveness, by Drug Class

7. Global Psoriasis Treatment Market Analysis and Forecast, by Route of Administration

7.1. Introduction & Definition

7.2. Key Findings / Developments

7.3. Psoriasis Treatment Market Value Forecast, by Route of Administration, 2017–2027

7.3.1. Oral

7.3.2. Parenteral

7.3.3. Topical

7.4. Market Attractiveness By Route of Administration

8. Global Psoriasis Treatment Market Analysis and Forecast, by Distribution Channel

8.1. Introduction & Definition

8.2. Key Findings / Developments

8.3. Psoriasis Treatment Market Value Forecast, by Distribution Channel, 2017–2027

8.3.1. Hospital Pharmacies

8.3.2. Retail Pharmacies

8.3.3. Others

8.4. Market Attractiveness, by Distribution Channel

9. Global Psoriasis Treatment Market Analysis and Forecast, by Region

9.1. Key Findings

9.2. Psoriasis Treatment Market Value Forecast, by Region

9.2.1. North America

9.2.2. Europe

9.2.3. Asia Pacific

9.2.4. Latin America

9.2.5. Middle East & Africa

9.3. Market Attractiveness, by Region

10. North America Psoriasis Treatment Market Analysis and Forecast

10.1. Introduction

10.1.1. Key Findings

10.2. North America Psoriasis Treatment Market Value Forecast, by Drug Class, 2017–2027

10.2.1. TNF Inhibitors

10.2.2. Interleukin Inhibitors

10.2.3. Vitamin D Analogs

10.2.4. Corticosteroids

10.2.5. Others

10.3. North America Psoriasis Treatment Market Value Forecast, by Route of Administration, 2017–2027

10.3.1. Oral

10.3.2. Parenteral

10.3.3. Topical

10.4. North America Psoriasis Treatment Market Value Forecast, by Distribution Channel, 2017–2027

10.4.1. Hospital Pharmacies

10.4.2. Retail Pharmacies

10.4.3. Others

10.5. North America Psoriasis Treatment Market Value Forecast, by Country/Sub-region, 2017–2027

10.5.1. U.S.

10.5.2. Canada

10.6. North America Psoriasis Treatment Market Attractiveness Analysis

10.6.1. By Drug Class

10.6.2. By Route of Administration

10.6.3. By Distribution Channel

10.6.4. By Country

11. Europe Psoriasis Treatment Market Analysis and Forecast

11.1. Introduction

11.1.1. Key Findings

11.1.2. Others

11.2. Europe Psoriasis Treatment Market Value Forecast, by Drug Class, 2017–2027

11.2.1. TNF Inhibitors

11.2.2. Interleukin Inhibitors

11.2.3. Vitamin D Analogs

11.2.4. Corticosteroids

11.2.5. Others

11.3. Europe Psoriasis Treatment Market Value Forecast, by Route of Administration, 2017–2027

11.3.1. Oral

11.3.2. Parenteral

11.3.3. Topical

11.4. Europe Psoriasis Treatment Market Value Forecast, by Distribution Channel, 2017–2027

11.4.1. Hospital Pharmacies

11.4.2. Retail Pharmacies

11.4.3. Others

11.5. Europe Psoriasis Treatment Market Value Forecast, by Country/Sub-region, 2017–2027

11.5.1. Germany

11.5.2. U.K.

11.5.3. France

11.5.4. Spain

11.5.5. Italy

11.5.6. Rest of Europe

11.6. Europe Psoriasis Treatment Market Attractiveness Analysis

11.6.1. By Drug Class

11.6.2. By Route of Administration

11.6.3. By Distribution Channel

11.6.4. By Country/Sub-region

12. Asia Pacific Psoriasis Treatment Market Analysis and Forecast

12.1. Introduction

12.1.1. Key Findings

12.2. Asia Pacific Psoriasis Treatment Market Value Forecast, by Drug Class, 2017–2027

12.2.1. TNF Inhibitors

12.2.2. Interleukin Inhibitors

12.2.3. Vitamin D Analogs

12.2.4. Corticosteroids

12.2.5. Others

12.3. Asia Pacific Psoriasis Treatment Market Value Forecast, by Route of Administration, 2017–2027

12.3.1. Oral

12.3.2. Parenteral

12.3.3. Topical

12.4. Asia Pacific Psoriasis Treatment Market Value Forecast, by Distribution Channel, 2017–2027

12.4.1. Hospital Pharmacies

12.4.2. Retail Pharmacies

12.4.3. Others

12.5. Asia Pacific Psoriasis Treatment Market Value Forecast, by Country/Sub-region, 2017–2027

12.5.1. China

12.5.2. Japan

12.5.3. India

12.5.4. Australia & New Zealand

12.5.5. Rest of Asia Pacific

12.6. Asia Pacific Psoriasis Treatment Market Attractiveness Analysis

12.6.1. By Drug Class

12.6.2. By Route of Administration

12.6.3. By Distribution Channel

12.6.4. By Country/Sub-region

13. Latin America Psoriasis Treatment Market Analysis and Forecast

13.1. Introduction

13.1.1. Key Findings

13.2. Latin America Psoriasis Treatment Market Value Forecast, by Drug Class, 2017–2027

13.2.1. TNF Inhibitors

13.2.2. Interleukin Inhibitors

13.2.3. Vitamin D Analogs

13.2.4. Corticosteroids

13.2.5. Others

13.3. Latin America Psoriasis Treatment Market Value Forecast, by Route of Administration, 2017–2027

13.3.1. Oral

13.3.2. Parenteral

13.3.3. Topical

13.4. Latin America Psoriasis Treatment Market Value Forecast, by Distribution Channel, 2017–2027

13.4.1. Hospital Pharmacies

13.4.2. Retail Pharmacies

13.4.3. Others

13.5. Latin America Psoriasis Treatment Market Value Forecast, by Country/Sub-region, 2017–2027

13.5.1. Brazil

13.5.2. Mexico

13.5.3. Rest of Latin America

13.6. Latin America Psoriasis Treatment Market Attractiveness Analysis

13.6.1. By Drug Class

13.6.2. By Route of Administration

13.6.3. By Distribution Channel

13.6.4. By Country/Sub-region

14. Middle East & Africa Psoriasis Treatment Market Analysis and Forecast

14.1. Introduction

14.1.1. Key Findings

14.2. Middle East & Africa Psoriasis Treatment Market Value Forecast, by Drug Class, 2017–2027

14.2.1. TNF Inhibitors

14.2.2. Interleukin Inhibitors

14.2.3. Vitamin D Analogs

14.2.4. Corticosteroids

14.2.5. Others

14.3. Middle East & Africa Psoriasis Treatment Market Value Forecast, by Route of Administration, 2017–2027

14.3.1. Oral

14.3.2. Parenteral

14.3.3. Topical

14.4. Middle East & Africa Psoriasis Treatment Market Value Forecast, by Distribution Channel, 2017–2027

14.4.1. Hospital Pharmacies

14.4.2. Retail Pharmacies

14.4.3. Others

14.5. Middle East & Africa Psoriasis Treatment Market Value Forecast, by Country/Sub-region, 2017–2027

14.5.1. GCC Countries

14.5.2. South Africa

14.5.3. Rest of Middle East & Africa

14.6. Middle East & Africa Psoriasis Treatment Market Attractiveness Analysis

14.6.1. By Drug Class

14.6.2. By Route of Administration

14.6.3. By Distribution Channel

14.6.4. By Country/Sub-region

15. Competition Landscape

15.1. Market Share Analysis, by Company, 2018

15.2. Company Profiles

15.2.1. Amgen, Inc.

15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.1.2. Financial Overview

15.2.1.3. Product Portfolio

15.2.1.4. Strategic Overview

15.2.1.5. SWOT Analysis

15.2.2. Eli Lilly and Company

15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.2.2. Financial Overview

15.2.2.3. Product Portfolio

15.2.2.4. Strategic Overview

15.2.2.5. SWOT Analysis

15.2.3. Novartis AG

15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.3.2. Financial Overview

15.2.3.3. Product Portfolio

15.2.3.4. Strategic Overview

15.2.3.5. SWOT Analysis

15.2.4. Merck & Co., Inc.

15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.4.2. Financial Overview

15.2.4.3. Product Portfolio

15.2.4.4. Strategic Overview

15.2.4.5. SWOT Analysis

15.2.5. Johnson & Johnson

15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.5.2. Financial Overview

15.2.5.3. Product Portfolio

15.2.5.4. Strategic Overview

15.2.5.5. SWOT Analysis

15.2.6. Pfizer, Inc.

15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.6.2. Financial Overview

15.2.6.3. Product Portfolio

15.2.6.4. Strategic Overview

15.2.6.5. SWOT Analysis

15.2.7. AstraZeneca plc

15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.7.2. Financial Overview

15.2.7.3. Product Portfolio

15.2.7.4. Strategic Overview

15.2.7.5. SWOT Analysis

15.2.8. AbbVie, Inc.

15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.8.2. Financial Overview

15.2.8.3. Product Portfolio

15.2.8.4. Strategic Overview

15.2.8.5. SWOT Analysis

15.2.9. LEO Pharma A/S

15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.9.2. Financial Overview

15.2.9.3. Product Portfolio

15.2.9.4. Strategic Overview

15.2.9.5. SWOT Analysis

15.2.10. Biogen, Inc.

15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.10.2. Financial Overview

15.2.10.3. Product Portfolio

15.2.10.4. Strategic Overview

15.2.10.5. SWOT Analysis